Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3U2S5)

Drug Name

PF-04859989 Drug Info

Synonyms

(3S)-3-amino-1-hydroxy-1,2,3,4-tetrahydroquinolin-2-one; (S)-3-Amino-1-hydroxy-3,4-dihydroquinolin-2(1H)-one; CHEMBL2047851; 34783-48-7 (free base); 34783-48-7; (3S)-3-amino-1-hydroxy-3,4-dihydroquinolin-2-one; GTPL9038; SCHEMBL2132616; ZINC6117343; BDBM50386292; AKOS006281463; compound 1 [PMID: 23466229]; NCGC00485082-01; Q27088318; (3s)-3-amino-1-hydroxy-3,4-dihydroquinolin-2(1h)-one; Z1601186413

Indication

Disease Entry	ICD 11	Status	REF
Cognitive impairment	6D71	Preclinical	[1]
Schizophrenia	6A20	Preclinical	[1]

Cross-matching ID

PubChem CID: 22868923
TTD Drug ID: DM3U2S5

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Kynurenine oxoglutarate transaminase II (AADAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US10065972, Example 560	DM9QCTJ	N. A.	N. A.	Patented	[3]
US8933095, 1	DMG3T7E	N. A.	N. A.	Patented	[4]
US10065972, Example 281	DMBWJK4	N. A.	N. A.	Patented	[3]
US8933095, 16	DMRN5F4	N. A.	N. A.	Patented	[4]
US10065972, Example 396	DMT8WVZ	N. A.	N. A.	Patented	[3]
US8933095, 18	DMOZ4FS	N. A.	N. A.	Patented	[5]
US8933095, 14	DMZUNJ4	N. A.	N. A.	Patented	[5]
BFF-122	DM6BGJ9	Cognitive impairment	6D71	Preclinical	[1]
(S)-4-(Ethylsulfonyl)benzoylalanine	DMEJYV4	Cognitive impairment	6D71	Preclinical	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Kynurenine oxoglutarate transaminase II (AADAT)	TTT3IXG	AADAT_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
2	Investigating KYNA production and kynurenergic manipulation on acute mouse brain slice preparations. Brain Res Bull. 2019 Mar;146:185-191.
3	Bicyclic or tricyclic heterocyclic compound. US10065972.
4	KAT II inhibitors. US8933095.
5	KAT II inhibitors. US8598200.
6	Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience. 2009 Mar 3;159(1):196-203.